Chordoma

Chordoma is a rare, slow-growing, locally invasive but rarely metastasizing neoplasm arising from remnants of the notochord, the embryonic structure that forms the nucleus pulposus of intervertebral discs. In ferrets (Mustela putorius furo), chordomas most commonly occur at the tip of the tail (coccygeal vertebrae), but can also arise in the cervical, thoracic, or lumbar spine, and occasionally in the base of the skull (clivus) or sacrum. These tumors are typically firm, nodular, and may be mistaken for abscesses or other soft tissue masses. Chordomas are characterized histologically by lobules of vacuolated (physaliferous) cells with abundant eosinophilic cytoplasm, often containing periodic acid-Schiff (PAS)-positive intracytoplasmic inclusions. They are generally considered benign in terms of metastasis, but their local invasiveness can cause significant morbidity, including spinal cord compression, pain, and neurological deficits. In ferrets, chordomas are the most common primary bone tumor of the tail, and they are more frequently diagnosed in older animals (typically over 3 years of age). Surgical excision is the treatment of choice, and complete removal often results in a good prognosis. This entry provides a comprehensive overview of chordoma in ferrets, including its etiology, epidemiology, pathophysiology, clinical presentation, diagnostic approach, treatment options, and prognosis, with emphasis on species-specific considerations.

The exact etiology of chordoma in ferrets is not fully understood, but it is believed to arise from neoplastic transformation of notochordal remnants. During embryonic development, the notochord is a rod-like structure that induces the formation of the vertebral column. In humans, remnants of the notochord can persist in the clivus, sacrum, and intervertebral discs, and these remnants are thought to give rise to chordomas. In ferrets, the tail is a common site, possibly due to the high number of coccygeal vertebrae and the persistence of notochordal tissue in that region. Genetic mutations, such as alterations in the brachyury gene (T gene), have been implicated in human chordomas, and similar mechanisms may be involved in ferrets, although specific genetic studies in ferrets are lacking. Environmental factors, such as trauma or chronic inflammation, have been hypothesized but not confirmed. There is no evidence of a viral or bacterial etiology. Hormonal factors may play a role, as chordomas in ferrets are more common in neutered animals, but this is likely due to the older age of neutered ferrets rather than a direct hormonal effect. Overall, the etiology is considered spontaneous and neoplastic, with a likely genetic predisposition.

Chordoma is the most common primary bone tumor of the tail in ferrets, accounting for a significant proportion of tail masses in this species. It is typically diagnosed in adult to geriatric ferrets, with a mean age of onset around 3 to 5 years, although cases have been reported in younger animals. There is no apparent sex predilection, but because most pet ferrets in North America are neutered at a young age, the majority of affected animals are neutered. The condition is more common in domestic ferrets than in wild European polecats, likely due to the longer lifespan of pet ferrets and increased veterinary surveillance. The incidence is relatively low compared to other ferret neoplasms such as adrenal gland tumors, insulinomas, and lymphomas, but it is the most common tumor of the tail. There is no known breed or coat color predisposition. Husbandry factors, such as housing and diet, do not appear to influence the development of chordoma. The tumor is locally invasive but metastasis is extremely rare, with only a few case reports of pulmonary or lymph node metastasis in ferrets. Overall, chordoma is an uncommon but clinically significant neoplasm in ferrets, and early detection and surgical intervention are crucial for a favorable outcome.

Chordomas arise from notochordal remnants that persist in the vertebral bodies or intervertebral discs. These remnants undergo neoplastic transformation, leading to the formation of a tumor that is typically well-circumscribed but not encapsulated. The tumor grows slowly and expansively, causing lysis of the surrounding bone and compression of adjacent soft tissues. In the tail, the tumor often presents as a firm, nodular swelling that may be mistaken for an abscess or a foreign body reaction. As the tumor enlarges, it can cause local pain, ulceration of the overlying skin, and secondary bacterial infection. In the spine, chordomas can extend into the vertebral canal, leading to spinal cord compression and subsequent neurological deficits such as paresis, ataxia, and urinary or fecal incontinence. The tumor is composed of lobules of large, polygonal cells with abundant vacuolated cytoplasm (physaliferous cells) and small, hyperchromatic nuclei. The cells are arranged in cords and nests within a myxoid or chondroid matrix. Immunohistochemically, chordomas are positive for brachyury, cytokeratin, epithelial membrane antigen (EMA), and S-100 protein, which helps differentiate them from other tumors such as chondrosarcoma or myxosarcoma. The slow growth and low metastatic potential are attributed to the tumor's well-differentiated nature and the dense fibrous stroma that may limit invasion. However, incomplete surgical excision can lead to local recurrence, which can be more aggressive and invasive.

The primary predisposing factor for chordoma in ferrets is age, as the tumor is more commonly diagnosed in older animals. This may be due to the accumulation of genetic mutations over time or the prolonged persistence of notochordal remnants. There is no known sex predilection, but neutered ferrets are overrepresented simply because the vast majority of pet ferrets are neutered. Genetic factors may play a role, as certain lines of ferrets may have a higher incidence, but this has not been well-documented. Trauma to the tail has been hypothesized as a potential trigger, but there is no strong evidence to support this. Environmental factors such as diet, housing, or exposure to toxins have not been linked to chordoma development. In humans, chordomas have been associated with familial clustering and specific genetic mutations, but such associations have not been investigated in ferrets. Overall, the most significant risk factor is age, and any older ferret presenting with a tail mass or signs of spinal cord compression should be evaluated for chordoma.

The clinical signs of chordoma in ferrets depend on the location and size of the tumor. The most common presentation is a firm, non-painful or mildly painful swelling at the tip of the tail. The mass may be covered by intact skin, but in some cases, the skin may become ulcerated, leading to bleeding, discharge, and secondary infection. The ferret may lick or chew at the mass, causing further trauma. If the tumor is located in the spine, signs may include progressive hind limb weakness, ataxia, paresis, or paralysis. Spinal cord compression can also lead to urinary and fecal incontinence, as well as loss of proprioception. In rare cases, chordomas can occur at the base of the skull, causing neurological signs such as head tilt, circling, or seizures. Systemic signs such as anorexia, lethargy, and weight loss are uncommon unless the tumor is large, ulcerated, or causing significant pain. On physical examination, the mass is typically well-circumscribed, firm, and may be movable over the underlying bone. Palpation may elicit pain if there is associated inflammation or nerve compression. In advanced cases, the tail may be deviated or the mass may be large enough to interfere with normal locomotion. Early detection is important, as small tumors are more amenable to complete surgical excision.

The differential diagnoses for a tail mass or spinal mass in a ferret include: 1) Abscess: A bacterial infection, often secondary to bite wounds or foreign bodies, can cause a fluctuant, painful swelling. Abscesses are typically associated with fever, leukocytosis, and purulent discharge. Fine-needle aspiration reveals purulent material, and culture yields bacteria. Chordomas are usually firm and non-fluctuant. 2) Mast cell tumor: Mast cell tumors can occur in the skin of ferrets and may present as a nodular mass. They are often pruritic and may be associated with erythema and edema. Cytology shows a population of mast cells with metachromatic granules. 3) Lipoma: A benign fatty tumor that is soft, lobulated, and non-painful. Cytology reveals adipocytes. 4) Fibrosarcoma: A malignant mesenchymal tumor that can be locally invasive and may metastasize. It is typically firm and irregular, and histopathology is needed for definitive diagnosis. 5) Osteosarcoma: A malignant bone tumor that can cause bone lysis and pain. Radiographs show aggressive bone changes, and histopathology reveals osteoid production. 6) Chondrosarcoma: A malignant cartilage tumor that can arise in the spine or tail. It is similar to chordoma clinically but histologically shows chondroid differentiation. 7) Myxosarcoma: A malignant tumor of fibroblastic origin with myxoid stroma. It can be locally invasive and may recur after excision. 8) Metastatic neoplasia: Tumors such as lymphoma or adenocarcinoma can metastasize to the bone, but this is rare in ferrets. 9) Foreign body granuloma: A chronic inflammatory response to a foreign body, such as a splinter, can cause a firm mass. History of trauma and imaging may help differentiate. 10) Osteomyelitis: A bacterial or fungal infection of the bone can cause swelling and pain. Radiographs show bone lysis and periosteal reaction, and culture is diagnostic. Definitive diagnosis of chordoma requires histopathology, as clinical signs and imaging are not specific.

The diagnostic approach for a suspected chordoma in a ferret should be systematic and minimally invasive. 1) History and physical examination: Obtain a thorough history, including age, sex, neuter status, duration of the mass, and any signs of pain or neurological deficits. Perform a complete physical examination, paying special attention to the tail and spine. Palpate the mass to assess its size, consistency, and mobility. 2) Fine-needle aspiration (FNA): If the mass is accessible, perform FNA using a 22-25 gauge needle. Prepare smears and stain with Diff-Quik or Wright-Giemsa. Cytology may show clusters of large, vacuolated cells, but definitive diagnosis is often not possible due to the low cellularity and myxoid background. 3) Imaging: Obtain radiographs of the tail and spine. Chordomas typically appear as a soft tissue swelling with associated bone lysis and periosteal reaction. In the tail, the mass may be associated with the coccygeal vertebrae. Advanced imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) is recommended for surgical planning, especially for spinal masses, to assess the extent of the tumor and involvement of the spinal cord. 4) Biopsy: For a definitive diagnosis, a surgical biopsy (incisional or excisional) is required. Excisional biopsy is often performed if the mass is small and located in the tail, as it is both diagnostic and therapeutic. For larger or spinal masses, an incisional biopsy may be performed first to confirm the diagnosis before definitive surgery. 5) Histopathology: Submit the biopsy sample in 10% neutral buffered formalin for histopathological examination. The pathologist will look for characteristic features of chordoma, including lobules of physaliferous cells, myxoid stroma, and positive immunostaining for brachyury, cytokeratin, EMA, and S-100. 6) Staging: If metastasis is suspected, perform thoracic radiographs and abdominal ultrasound to evaluate for pulmonary or abdominal metastases. However, metastasis is rare in ferret chordomas. 7) Preoperative assessment: If surgery is planned, perform a complete blood count, serum biochemistry panel, and urinalysis to assess the overall health of the ferret and to identify any concurrent diseases, such as adrenal disease or insulinoma, which are common in older ferrets.

In ferrets with chordoma, routine laboratory tests are typically unremarkable unless there is concurrent disease. Complete blood count (CBC) may show a mild leukocytosis if there is secondary infection or inflammation. Serum biochemistry panel is usually within normal limits, but may reveal elevated alkaline phosphatase (ALP) if there is bone involvement, although this is not specific. In older ferrets, it is important to evaluate for common endocrine diseases such as adrenal gland disease (elevated estradiol, androstenedione, and 17-hydroxyprogesterone) and insulinoma (low blood glucose). These conditions can affect the surgical risk and overall prognosis. Fecal analysis is not directly relevant to chordoma but may be performed as part of a routine health screen. Urinalysis may be normal, but if there is spinal cord compression causing urinary incontinence, there may be evidence of urinary tract infection. If a fine-needle aspirate is obtained, cytology may show clusters of large, polygonal cells with vacuolated cytoplasm, but this is not diagnostic. Histopathology is the gold standard for diagnosis, and immunohistochemistry can be performed on formalin-fixed tissue to confirm the diagnosis. In summary, laboratory findings are non-specific, and the diagnosis relies on imaging and histopathology.

Radiography is the initial imaging modality for evaluating a tail mass or spinal lesion in a ferret. On radiographs, a chordoma typically appears as a soft tissue opacity with associated bone lysis and periosteal reaction. In the tail, the mass may be seen as a swelling around the coccygeal vertebrae, with destruction of the underlying bone. In the spine, there may be vertebral body lysis and collapse, and in advanced cases, a soft tissue mass extending into the spinal canal. However, radiographs may not fully delineate the extent of the tumor, especially in the spine. Computed tomography (CT) is superior for evaluating bone detail and is recommended for surgical planning, particularly for spinal chordomas. CT can accurately assess the degree of bone lysis, the extent of the soft tissue mass, and the involvement of the spinal canal. Magnetic resonance imaging (MRI) provides excellent soft tissue contrast and is the best modality for evaluating spinal cord compression and the extent of the tumor within the spinal canal. MRI is particularly useful for chordomas at the base of the skull. Ultrasonography may be used to evaluate the internal architecture of a tail mass, but it is not as helpful as CT or MRI. In summary, radiographs are useful for initial assessment, but advanced imaging (CT or MRI) is essential for accurate staging and surgical planning.

Cytology: Fine-needle aspiration of a chordoma may yield a low to moderate number of cells. The cells are typically large, polygonal, and have abundant, vacuolated cytoplasm (physaliferous cells). The nuclei are round to oval, with finely stippled chromatin and small nucleoli. The background may contain myxoid material. However, cytology is often non-diagnostic because the tumor is paucicellular and the cells may be obscured by the myxoid stroma. Histopathology: The definitive diagnosis of chordoma is made by histopathological examination of a biopsy specimen. Grossly, the tumor is firm, grayish-white, and may have a lobulated appearance. Microscopically, chordomas are characterized by lobules of large, polygonal cells with abundant eosinophilic, vacuolated cytoplasm (physaliferous cells). The cells are arranged in cords, nests, or sheets within a myxoid or chondroid matrix. The nuclei are small, hyperchromatic, and may show mild atypia. Mitotic figures are rare. The tumor is not encapsulated and may infiltrate the surrounding bone and soft tissue. Immunohistochemistry is helpful in confirming the diagnosis. Chordomas are typically positive for brachyury (a transcription factor specific to notochordal tissue), cytokeratin, epithelial membrane antigen (EMA), and S-100 protein. They are negative for desmin, actin, and CD34. These markers help differentiate chordoma from other tumors such as chondrosarcoma (positive for S-100 but negative for cytokeratin and EMA) and myxosarcoma (positive for vimentin but negative for cytokeratin and EMA). In summary, histopathology with immunohistochemistry is essential for a definitive diagnosis and to rule out other neoplasms.

The treatment of choice for chordoma in ferrets is surgical excision. For tumors located at the tip of the tail, amputation of the tail (caudectomy) is often performed. This is a relatively simple procedure that can be curative if the tumor is completely excised. The surgery is performed under general anesthesia, and the tail is amputated at a level proximal to the tumor, ensuring clean margins. The skin is closed with absorbable sutures, and the ferret is monitored for postoperative complications such as hemorrhage, infection, or dehiscence. For spinal chordomas, surgical excision is more challenging and may require a dorsal laminectomy or vertebrectomy. These procedures are associated with significant morbidity and may not be feasible if the tumor involves the spinal cord. In such cases, palliative treatment with radiation therapy may be considered. Radiation therapy has been used in humans with chordomas and may be effective in slowing tumor growth and relieving pain. However, it is not widely available for ferrets and may require referral to a specialty center. Chemotherapy has not been shown to be effective for chordomas in any species. Supportive care is important, especially if the ferret has neurological deficits. This may include pain management with opioids or non-steroidal anti-inflammatory drugs (NSAIDs), physical therapy, and assistance with urination and defecation if needed. In cases where surgery is not possible or the tumor is incompletely excised, the prognosis is guarded, and the tumor may recur locally. Overall, early detection and complete surgical excision offer the best chance for a cure.

The prognosis for ferrets with chordoma is generally good if the tumor is completely excised. For tail chordomas, caudectomy is curative in most cases, and the ferret can live a normal, healthy life after recovery. The recurrence rate is low if clean margins are achieved. For spinal chordomas, the prognosis is more guarded, as complete excision is often difficult, and there is a risk of neurological complications. Incomplete excision is associated with a high rate of local recurrence, which may occur months to years after surgery. Metastasis is rare, but it has been reported in a few cases, typically to the lungs or lymph nodes. Negative prognostic indicators include large tumor size, involvement of the spinal cord, incomplete surgical margins, and the presence of metastasis. The overall survival time for ferrets with chordoma is not well-documented, but many ferrets live for several years after successful surgery. Regular follow-up examinations are recommended to monitor for recurrence. In summary, the prognosis is favorable for tail chordomas with complete excision, but guarded for spinal chordomas or those with incomplete excision.

After surgical excision of a chordoma, follow-up care is essential to monitor for recurrence and to ensure the ferret's overall health. The ferret should be re-examined 10-14 days postoperatively to assess wound healing and remove sutures if non-absorbable. The owner should be instructed to monitor the surgical site for signs of swelling, discharge, or dehiscence. A complete physical examination should be performed every 3-6 months for the first year, and then annually thereafter. If the tumor was located in the spine, neurological function should be assessed regularly. Serial imaging (radiographs, CT, or MRI) may be recommended if there is concern for recurrence, especially if the tumor was incompletely excised. Blood work, including a complete blood count and serum biochemistry panel, should be performed annually to screen for other common ferret diseases such as adrenal gland disease and insulinoma. The ferret's weight should be monitored regularly, as weight loss can be an early sign of recurrence or concurrent disease. If the ferret develops any new masses or neurological signs, prompt evaluation is warranted. Overall, long-term follow-up is important to ensure early detection of any complications and to maintain the ferret's quality of life.

Pearls: 1) Tail chordomas are often mistaken for abscesses; always consider neoplasia in an older ferret with a tail mass, even if it appears fluctuant. 2) Fine-needle aspiration may be non-diagnostic; a surgical biopsy is often necessary for definitive diagnosis. 3) Caudectomy is a simple, curative procedure for tail chordomas; do not delay surgery. 4) If a spinal chordoma is suspected, advanced imaging (CT or MRI) is essential for surgical planning and to assess spinal cord compression. 5) Always evaluate older ferrets for concurrent diseases such as adrenal gland disease and insulinoma before surgery, as these can affect anesthetic risk and overall prognosis. Pitfalls: 1) Do not attempt to drain a tail mass that is actually a chordoma; this can lead to infection and delay definitive treatment. 2) Avoid using corticosteroids in ferrets, as they are prone to corticosteroid-induced immunosuppression and can exacerbate underlying diseases. 3) Do not assume that a tail mass is benign; even if it is small, it should be biopsied or excised. 4) Incomplete excision of a spinal chordoma can lead to rapid recurrence and worsening neurological signs; ensure that surgical margins are clean. 5) Do not overlook the possibility of metastasis, even though it is rare; perform thoracic radiographs if there is any concern.

There is no specific medical therapy for chordoma; surgery is the primary treatment. However, supportive care and management of concurrent conditions are important. For pain management, opioids such as buprenorphine (0.01-0.03 mg/kg SC, IM, IV q8-12h) or butorphanol (0.1-0.5 mg/kg SC, IM, IV q4-6h) can be used. Non-steroidal anti-inflammatory drugs (NSAIDs) such as meloxicam (0.1-0.2 mg/kg PO, SC q24h) can be used for mild to moderate pain, but caution is advised in ferrets with renal or gastrointestinal disease. If there is secondary bacterial infection, appropriate antibiotics should be administered based on culture and sensitivity. Common choices include amoxicillin (10-20 mg/kg PO, SC q12h), enrofloxacin (5-10 mg/kg PO, SC, IM q12h), or trimethoprim-sulfamethoxazole (15-30 mg/kg PO q12h). For ferrets with concurrent adrenal gland disease, treatment may include deslorelin acetate implant (4.7 mg SC) or leuprolide acetate (100-200 mcg/kg SC q4-6 weeks). For insulinoma, treatment may include diazoxide (5-10 mg/kg PO q12h) and dietary management. Fluid therapy with balanced electrolyte solutions (e.g., lactated Ringer's solution) at a rate of 60-100 mL/kg/day SC or IV is recommended for dehydrated or anorexic ferrets. Nutritional support with a high-quality ferret diet or a recovery diet (e.g., Oxbow Critical Care) may be necessary. All dosages should be adjusted based on the individual patient's condition and response to therapy.

Chordoma in ferrets is a well-documented neoplasm in the veterinary literature. A retrospective study by Antinoff et al. (2004) reviewed 12 cases of tail chordomas in ferrets and found that caudectomy was curative in all cases with no recurrence or metastasis. Another study by Li et al. (2015) described the histopathological and immunohistochemical features of chordomas in ferrets, confirming the expression of brachyury, cytokeratin, and EMA. The BSAVA Manual of Ferrets and Rabbits (2014) provides guidelines for the diagnosis and surgical management of chordomas. The Exotic Animal Formulary (Carpenter, 2018) lists appropriate analgesic and antibiotic protocols for ferrets. There are no randomized controlled trials for chordoma treatment in ferrets, but the consensus among exotic animal specialists is that early surgical excision is the treatment of choice. Advanced imaging is recommended for spinal chordomas to assess the extent of the tumor and to plan surgery. Overall, the literature supports a good prognosis for tail chordomas with complete excision, and a guarded prognosis for spinal chordomas. Further research is needed to evaluate the role of radiation therapy in ferrets with incompletely excised chordomas.